Gheybi Mohammad Kazzem, Baradaran Azar, Mohajeri Mohammad Reza, Ostovar Afshin, Hajalikhani Parvaneh, Farrokhi Shokrollah
Persian Gulf Tropical Medicine Research Centre, Bushehr University of Medical Sciences, Bushehr, Iran.
Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.
APMIS. 2016 May;124(5):365-71. doi: 10.1111/apm.12518. Epub 2016 Jan 27.
Human epidermal growth factor receptor-2 is an important and prognostic factors and one of the most targeted proteins in breast cancer's therapy. There is no globally accepted method for determining its status. Here, we aimed to evaluate the immunohistochemistry method validity in predicting HER-2 status by Fluorescence in situ hybridization method and investigate some clinicopathological variables association with HER-2 amplification. A total of 190 HER-2 2+ and 3+ by immunohistochemistry (IHC) invasive breast cancer cases were enrolled in this study. Fluorescence in situ hybridization (FISH) was performed for these cases using FDA criteria and the association between clinicopathological variables and HER-2 status evaluated. Study consisted of 190 invasive breast cancer patients (160 HER-2 2+ and 30 HER-2 3+). HER-2 FISH amplification according to FDA criteria was found 27.5% (44/160 patients) in HER-2 2+ patients and 83.3% (25/30 patients) in HER-2 3+ patients. Tumors with HER-2 amplification were more likely to be ER-negative (51.0% vs 31.2%, p = 0.013) and PR-negative (52.9% vs 27.0%, p < 0.001). This study showed that immunohistochemistry is not a good method for evaluating HER-2 status and decision-making about trastuzumab therapy even with 3+ score patients. However, this result may not be too strong for IHC 3+ cases due to the limited number of these patients in this study.
人表皮生长因子受体2是一个重要的预后因素，也是乳腺癌治疗中最具靶向性的蛋白之一。目前尚无全球公认的确定其状态的方法。在此，我们旨在通过荧光原位杂交法评估免疫组织化学方法在预测HER-2状态方面的有效性，并研究一些与HER-2扩增相关的临床病理变量。本研究共纳入190例免疫组织化学（IHC）检测为HER-2 2+和3+的浸润性乳腺癌病例。对这些病例采用FDA标准进行荧光原位杂交（FISH）检测，并评估临床病理变量与HER-2状态之间的相关性。研究包括190例浸润性乳腺癌患者（160例HER-2 2+和30例HER-2 3+）。根据FDA标准，HER-2 2+患者中HER-2 FISH扩增率为27.5%（44/160例患者），HER-2 3+患者中为83.3%（25/30例患者）。HER-2扩增的肿瘤更可能为雌激素受体阴性（51.0%对31.2%，p = 0.013）和孕激素受体阴性（52.9%对27.0%，p < 0.001）。本研究表明，即使对于评分为3+的患者，免疫组织化学也不是评估HER-2状态和决定曲妥珠单抗治疗的好方法。然而，由于本研究中这类患者数量有限，这一结果对于IHC 3+病例可能不太有说服力。
